[V View 2021 Annual Report] In 2021, 60% of pharmaceutical stocks will increase in revenue and net profit, and BeiGene will become the "loss king"-Stock Channel-Hexun.com

  • Post date May 1, 2022 — 04:00 Post Lock Login to View

Key Data Concepts:   
? These are the company names, stock quotes, topics, and entities related to this data.

000513 000516 000925 000950 002004 002044 002198 002393 002437 002900 300030 300033 300122 300246 300318 300347 300562 300713 300759 300760 Beijing Bohui Innovation Biotechnology Beijing Hotgen Biotech Chongqing Zhifei Biological Products CQ Pharmaceutical Holding Guangdong Biolight Meditech Guangdong Jiaying Pharmaceutical Guangdong Transtek Medical Electronics Guangyuyuan Chinese Herbal Medicine Guangzhou Improve Medical Instruments Hangzhou Tigermed Consulting Harbin Gloria Pharmaceuticals Harbin Medisan Pharmaceutical Hithink Royalflush Information Network Huapont Life Sciences Jiangsu Hengrui Medicine Joincare Pharmaceutical Group Industry Livzon Pharmaceutical Group Meinian Onehealth Healthcare Holdings Pharmaron Beijing Shanghai Fosun Pharmaceutical Shanghai Pharmaceuticals Holding Shenzhen Mindray Bio-Medical Electronics Tianjin Lisheng Pharmaceutical Wuxi Apptec Xi'an International Medical Investment Company Limited Accounting, Audit Earnings Annual, Special Corporate Meeting Annual Report Research, Development Health, Beauty Product Pharmaceutical Construction, Property Financial, Business Service Market, Exchange Stocks Medicine People Trend Biology Small, Medium Enterprise Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login



Related Data